{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:13:26Z","timestamp":1793873606723,"version":"4.6.1"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:00:00Z","timestamp":1341878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      Insulin degludec (\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      ) is a new\u2010generation, ultra\u2010long\u2010acting basal insulin that forms soluble multihexamers upon subcutaneous injection, resulting in a depot from which\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      is absorbed slowly and continuously into circulation. This double\u2010blind, two\u2010period, incomplete block cross\u2010over trial investigated the pharmacodynamic and pharmacokinetic properties of\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      at steady state (\n                      <jats:styled-content style=\"fixed-case\">SS<\/jats:styled-content>\n                      ) in people with type 2 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty\u2010nine subjects treated with insulin without concomitant oral anti\u2010diabetic drugs were given\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      (0.4, 0.6 and\/or 0.8 U\/kg) once daily for two 6\u2010day periods, separated by an interval of 13\u201321 days. Following dosing on Day 6, subjects underwent a 26\u2010h euglycaemic glucose clamp (Biostator\u00ae; clamp blood glucose level: 90 mg\/dl; 5.0 mmol\/l). Pharmacokinetic samples were taken until 120 h after last dosing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For all dose levels, the mean glucose infusion rate (\n                      <jats:styled-content style=\"fixed-case\">GIR<\/jats:styled-content>\n                      ) profiles were flat and stable. The glucose\u2010lowering effect of\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      was evenly distributed over the dosing interval \u03c4, with area under the curve (\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      ) for each of the four 6\u2010h intervals being approximately 25% of the total\n                      <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">\n                        AUC\n                        <jats:sub>GIR<\/jats:sub>\n                      <\/jats:styled-content>\n                      <jats:sub>,\u03c4,<\/jats:sub>\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:sub>SS<\/jats:sub>\n                      <\/jats:styled-content>\n                      ). Total glucose\u2010lowering effect increased linearly with increasing dose. The blood glucose levels of all subjects stayed very close to the clamp target until end of clamp. The terminal half\u2010life of\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      was approximately 25 h at steady state.\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      was well tolerated and no safety concerns were identified. No injection site reactions were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">IDeg<\/jats:styled-content>\n                      has a flat and consistent glucose\u2010lowering effect in people with type 2 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1463-1326.2012.01638.x","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T19:55:25Z","timestamp":1340308525000},"page":"944-950","source":"Crossref","is-referenced-by-count":270,"title":["Ultra\u2010long\u2010acting insulin degludec has a flat and stable glucose\u2010lowering effect in type 2 diabetes"],"prefix":"10.1111","volume":"14","author":[{"given":"T.","family":"Heise","sequence":"first","affiliation":[{"name":"Profil Institute for Metabolic Research  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nosek","sequence":"additional","affiliation":[{"name":"Profil Institute for Metabolic Research  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"B\u00f8ttcher","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hastrup","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Haahr","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00756.x"},{"issue":"1","key":"e_1_2_7_3_1","first-page":"A11","article-title":"Insulin degludec is a new generation ultra\u2010long acting basal insulin with a unique mechanism of protraction based on multi\u2010hexamer formation","volume":"59","author":"Jonassen I","year":"2010","journal-title":"Diabetes"},{"key":"e_1_2_7_4_1","first-page":"S426","article-title":"Multi\u2010hexamer formation is the underlying basis for the ultra\u2010long glucose\u2010lowering effect of insulin degludec","volume":"54","author":"Kurtzhals P","year":"2011","journal-title":"Diabetologia"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.12.2142"},{"key":"e_1_2_7_6_1","volume-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland M","year":"2011"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01839.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.6.1614"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2208"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_2_7_12_1","first-page":"S53","article-title":"Insulin degludec does not compromise efficacy or safety when given in a flexible once\u2010daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes","volume":"54","author":"Atkin SL","year":"2011","journal-title":"Diabetologia"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62305-7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00685.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2011"},{"key":"e_1_2_7_16_1","unstructured":"Lantus\u2014scientific discussion 2003. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000284\/WC500036075.pdf. Accessed 28 November 2011."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60205-0"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01726.x"},{"key":"e_1_2_7_20_1","first-page":"CD006383","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","author":"Swinnen SG","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.00936.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<592::AID-DIA625>3.0.CO;2-J"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2012.01638.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1463-1326.2012.01638.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1463-1326.2012.01638.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2012.01638.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:57:41Z","timestamp":1761868661000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2012.01638.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1463-1326.2012.01638.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01638.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,10]]}}}